Levosimendan calcium sensitiser

Description Results NMA

Intravenous Levosimendan (n=299)

vs.

placebo (n=301)

double blind

Parallel groups

Sample size: 299/301

Primary endpoint: worsening heart failure

FU duration: 5 days

levosimendan 0.1–0.2 mg/kg/min (n=-9)

vs.

placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint: composite clinical

FU duration:

Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: hypotension or myocardial ischaemia

FU duration: 14 days

all cause death (6M+) 0.91 [0.74; 1.12]

Short term death (30d) 0.85 [0.63; 1.15]

Intravenous levosimendan (n=664)

vs.

intravenous dobutamine (n=663)

double-blind

Parallel groups

Sample size: 664/663

Primary endpoint: all cause mortality

FU duration: 180 days

Levosimendan 16 mg/kg þ 0.2 mg/kg/min (n=-9)

vs.

Dobutamine (10 mg/kg/min) and placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

Levosimendan (n=-9)

vs.

Dobutamine (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: haemodynamic improvement

FU duration: 24h